821 related articles for article (PubMed ID: 23380027)
1. Parkinson disease: from pathology to molecular disease mechanisms.
Dexter DT; Jenner P
Free Radic Biol Med; 2013 Sep; 62():132-144. PubMed ID: 23380027
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
3. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
4. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
5. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dysfunction in genetic animal models of Parkinson's disease.
Trancikova A; Tsika E; Moore DJ
Antioxid Redox Signal; 2012 May; 16(9):896-919. PubMed ID: 21848447
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease.
Ryan BJ; Hoek S; Fon EA; Wade-Martins R
Trends Biochem Sci; 2015 Apr; 40(4):200-10. PubMed ID: 25757399
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.
Yan MH; Wang X; Zhu X
Free Radic Biol Med; 2013 Sep; 62():90-101. PubMed ID: 23200807
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease.
Thomas B; Beal MF
Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R183-94. PubMed ID: 17911161
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease.
McNaught KS; Olanow CW
Ann Neurol; 2003; 53 Suppl 3():S73-84; discussion S84-6. PubMed ID: 12666100
[TBL] [Abstract][Full Text] [Related]
12. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.
Ciron C; Zheng L; Bobela W; Knott GW; Leone TC; Kelly DP; Schneider BL
Acta Neuropathol Commun; 2015 Apr; 3():16. PubMed ID: 25853296
[TBL] [Abstract][Full Text] [Related]
13. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
[TBL] [Abstract][Full Text] [Related]
15. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
16. [Pathological mechanisms of Parkinson's disease].
Matsui H; Takahashi R
Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
[TBL] [Abstract][Full Text] [Related]
17. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.
Ferrer I; Martinez A; Blanco R; Dalfó E; Carmona M
J Neural Transm (Vienna); 2011 May; 118(5):821-39. PubMed ID: 20862500
[TBL] [Abstract][Full Text] [Related]
18. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
[TBL] [Abstract][Full Text] [Related]
19. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
20. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.
Mudò G; Mäkelä J; Di Liberto V; Tselykh TV; Olivieri M; Piepponen P; Eriksson O; Mälkiä A; Bonomo A; Kairisalo M; Aguirre JA; Korhonen L; Belluardo N; Lindholm D
Cell Mol Life Sci; 2012 Apr; 69(7):1153-65. PubMed ID: 21984601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
